Search results for "Progestin"

showing 10 items of 32 documents

Steroid hormone receptor analysis in human melanoma and non-malignant human skin

1982

MaleReceptors SteroidSkin NeoplasmsSteroid hormone receptorbusiness.industryReceptors Cell SurfaceNon malignantHuman skinDermatologyReceptors GlucocorticoidReceptors EstrogenImmunologyCancer researchHumansMedicineFemaleHuman melanomaProgestinsbusinessMelanomaSkinBritish Journal of Dermatology
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

Fertility sparing treatments in endometrial cancer patients: the potential role of the new molecular classification

2021

Endometrial cancer is the most frequent gynecological malignancy, and, although epidemiologically it mainly affects advanced age women, it can also affect young patients who want children and who have not yet completed their procreative project. Fertility sparing treatments are the subject of many studies and research in continuous evolution, and represent a light of hope for young cancer patients who find themselves having to face an oncological path before fulfilling their desire for motherhood. The advances in molecular biology and the more precise clinical and prognostic classification of endometrial cancer based on the 2013 The Cancer Genome Atlas classification allow for the selection…

Oncologymedicine.medical_specialtyQH301-705.5obstetric outcomesReviewHysteroscopyCatalysisFertility sparing surgeryInorganic ChemistryMolecular classificationPrognostic classificationInternal medicineCancer genomeOutcome Assessment Health CaremedicineHumansmolecular biologyPhysical and Theoretical ChemistryBiology (General)QD1-999SpectroscopyPregnancybusiness.industryEndometrial cancerOrganic ChemistryFertility PreservationCancerGeneral Medicinemedicine.diseaseEndometrial cancer; Fertility sparing; Molecular biology; Obstetric outcomes; PregnancyCombined Modality Therapyfertility sparingEndometrial NeoplasmsComputer Science Applicationsendometrial cancer; molecular biology; fertility sparing; obstetric outcomes; pregnancyChemistryFertilityGynecological malignancyendometrial cancerFemalepregnancyProgestinsbusinessOrgan Sparing Treatments
researchProduct

Estroprogestins and cardiovascular risk in Polycystic Ovary Syndrome

2013

Because PCOS women present an increased cardiovascular risk, the safety of estroprogestin treatment is debated and contrasting data have been reported. However, cardiovascular risk is not the same in all PCOS women and individual cardiovascular risk should be assessed before staring any estroprogestin treatment. The available data show that products containing both second generation and third generation progestins (including drosperinone and cyproterone acetate) represent a safe treatment in PCOS patients with regular cardiovascular risk. In PCOS patients with increased cardiovascular risk, a careful choice of estroprogestin product is needed and cardiovascular risk should be monitored duri…

PCOS Estroprogestins Cardiovascular risk contraception hyperandrogenismSettore MED/40 - Ginecologia E OstetriciaSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/13 - Endocrinologia
researchProduct

Patologia benigna della mammella ed estroprogestinici.

2006

Patologia mammaria estroprogestiniciSettore MED/40 - Ginecologia E Ostetricia
researchProduct

Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta‐…

2017

Objective To assess the efficacy of vaginal progesterone for the prevention of preterm birth and neonatal morbidity and mortality in asymptomatic women with a twin gestation and a sonographic short cervix (cervical length ≤ 25 mm) in the mid-trimester. Methods This was an updated systematic review and meta-analysis of individual patient data (IPD) from randomized controlled trials comparing vaginal progesterone with placebo/no treatment in women with a twin gestation and a mid-trimester sonographic cervical length ≤ 25 mm. MEDLINE, EMBASE, POPLINE, CINAHL and LILACS (all from inception to 31 December 2016), the Cochrane Central Register of Controlled Trials, Research Registers of ongoing tr…

Perinatal DeathCervix Uterilaw.inventiontransvaginal ultrasound0302 clinical medicineRandomized controlled trialObstetrics and gynaecologyPregnancylawInfant Mortality030212 general & internal medicineProgesteroneRandomized Controlled Trials as Topic030219 obstetrics & reproductive medicineRadiological and Ultrasound TechnologyObstetricsObstetrics and GynecologyGeneral MedicineMaternal MortalityTreatment OutcomePremature BirthGestationFemalemedicine.symptompreterm deliverymedicine.medical_specialtySystematic ReviewsBirth weightPlaceboAsymptomatic03 medical and health sciencesmedicineHumansRadiology Nuclear Medicine and imagingGynecologyFetusbusiness.industryprematurityInfant NewbornInfantprogestogenscervical lengthAdministration IntravaginalReproductive MedicineprogestinsRelative riskMaternal DeathPregnancy TwinSystematic ReviewbusinessUltrasound in Obstetrics & Gynecology
researchProduct

The effects of castration and of progestin-oestrogen combinations upon avoidance condtioning in female rats

1970

Summary Using avoidance conditioning the authors show that female rats, three months after castration, emit a lower number of responses. Isolation has no effect whatever on rats, whether normal or castrated. Brief treatment with progestin-oestrogen combinations, interrupted 60 hours before the commencement of the session, brings the behaviour of castrated rats back to the norm. Identical effects occur with the use of a cortical stimulating drug (methylphenidate); while, the action of this drug soon ceases, the effect of hormonal treatment lasts for the duration of the experiments. The results are discussed with reference to the significance to be attributed to the experiments.

Pharmacologymedicine.medical_specialtyMethylphenidatemedicine.drug_classAvoidance Conditioningchemistry.chemical_compoundCastrationEndocrinologychemistryInternal medicinemedicineBrief treatmentPsychologyProgestinHormonemedicine.drugPharmacological Research Communications
researchProduct

Doubtful association between progesterone therapy and fetal nuchal translucency

2015

Pregnancymedicine.medical_specialtyFetusbusiness.industryObstetricsProgesterone therapyObstetrics and Gynecologymedicine.diseaseNuchal translucencyPregnancyNuchal Translucency MeasurementmedicineHumansFemaleProgestinsNuchal Translucency MeasurementbusinessProgesteroneAmerican Journal of Obstetrics and Gynecology
researchProduct

Fertility-sparing approach in women affected by stage i and low-grade endometrial carcinoma: An updated overview

2021

Endometrial cancer (EC) is a deleterious condition which strongly affects a woman’s quality of life. Although aggressive interventions should be considered to treat high-grade EC, a conservative approach should be taken into consideration for women wishing to conceive. In this scenario, we present an overview about the EC fertility-sparing approach state of art. Type I EC at low stage is the only histological type which can be addressed with a fertility-sparing approach. Moreover, no myometrium and/or adnexal invasion should be seen, and lymph-vascular space should not be involved. Regarding the pharmaceutical target, progestins, in particular medroxyprogesterone acetate (MPA) or megestrol …

Psychological interventionReviewIUDQuality of lifeEndometrial cancerMedroxyprogesterone acetateFertility preservationBiology (General)Fertility preservationSpectroscopyObstetricsFertility PreservationGeneral Medicinefertility sparingART; Endometrial cancer; Fertility preservation; Fertility sparing; Infertility; IUD; Metformin; ProgestinMetforminComputer Science ApplicationsChemistryMyometriumFemaleARTmedicine.drugHumanInfertilityAdultmedicine.medical_specialtyQH301-705.5medicine.drug_classFertility sparingMedroxyprogesterone AcetateCatalysisInorganic ChemistrymedicineHumansEndometrial NeoplasmPhysical and Theoretical ChemistryQD1-999Molecular BiologyNeoplasm Staging...business.industryEndometrial cancerOrganic Chemistrymedicine.diseaseEndometrial NeoplasmsProgestinFertilityMegestrol acetateInfertilityQuality of LifeProgestinsbusinessProgestin
researchProduct

ENDOCRINE PROFILE, BMD EVALUATION, ESTROPROGESTINIC TREATMENT IN THE FOLLOW UP OF GIRLS WITH CONGENITAL COAGULOPATHIES

2011

Settore MED/38 - Pediatria Generale E SpecialisticaBMDESTROPROGESTINICCONGENITAL COAGULOPATHIES
researchProduct